EIDX
Eidos Therapeutics Inc
Clinical-stage biopharmaceutical company focused on transthyretin amyloidosis treatments
CUSIP: 28249H104HealthcareUS1 holder
Total Value
$40.40M
Total Shares
1.99M
Net Share Change
+1.99M
Activity
1 buying
Investor
Value
Shares
Weight
Change
Viking Global Investors
$40.40M1.99M sharesNEW